ERBB2 and breast carcinoma: CB-839 demonstrated antiproliferative activity in a triple-negative breast cancer (TNBC) cells and human epidermal growth factor receptor 2 (HER2)-positive breast cancer cells as a single agent or combined with paclitaxel [82].